269 related articles for article (PubMed ID: 12418935)
21. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.
Kinon BJ; Gilmore JA; Liu H; Halbreich UM
Psychoneuroendocrinology; 2003 Apr; 28 Suppl 2():69-82. PubMed ID: 12650682
[TBL] [Abstract][Full Text] [Related]
22. The effects of risperidone and olanzapine on the indications for clozapine.
Ganguli R; Brar JS
Psychopharmacol Bull; 1998; 34(1):83-7. PubMed ID: 9564203
[TBL] [Abstract][Full Text] [Related]
23. Risperidone side effects.
Conley RR
J Clin Psychiatry; 2000; 61 Suppl 8():20-3; discussion 24-5. PubMed ID: 10811239
[TBL] [Abstract][Full Text] [Related]
24. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
Cuesta MJ; Peralta V; Zarzuela A
Schizophr Res; 2001 Mar; 48(1):17-28. PubMed ID: 11278151
[TBL] [Abstract][Full Text] [Related]
25. Olanzapine and risperidone.
Love RC; Kelly DL
Am J Health Syst Pharm; 2003 Mar; 60(5):487-8; author reply 488-9. PubMed ID: 12635459
[No Abstract] [Full Text] [Related]
26. Quality of life and atypical antipsychotics.
Rudnick A
J Clin Psychopharmacol; 1998 Oct; 18(5):424-5. PubMed ID: 9790165
[No Abstract] [Full Text] [Related]
27. Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates.
Kasper S; Küfferle B
J Clin Psychopharmacol; 1998 Aug; 18(4):353-6. PubMed ID: 9690709
[No Abstract] [Full Text] [Related]
28. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
29. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.
Aubry JM; Simon AE; Bertschy G
J Clin Psychiatry; 2000 Sep; 61(9):649-55. PubMed ID: 11030485
[TBL] [Abstract][Full Text] [Related]
30. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
Ritchie CW; Chiu E; Harrigan S; Hall K; Hassett A; Macfarlane S; Mastwyk M; O'Connor DW; Opie J; Ames D
Int J Geriatr Psychiatry; 2003 May; 18(5):432-40. PubMed ID: 12766921
[TBL] [Abstract][Full Text] [Related]
31. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.
Caro JJ; Ward A; Levinton C; Robinson K
J Clin Psychiatry; 2002 Dec; 63(12):1135-9. PubMed ID: 12523873
[TBL] [Abstract][Full Text] [Related]
32. Glucose intolerance with atypical antipsychotics.
Hedenmalm K; Hägg S; Ståhl M; Mortimer O; Spigset O
Drug Saf; 2002; 25(15):1107-16. PubMed ID: 12452735
[TBL] [Abstract][Full Text] [Related]
33. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.
Kasper S; Hale A; Azorin JM; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 2():II1-II14. PubMed ID: 10603070
[No Abstract] [Full Text] [Related]
34. Weight gain and antipsychotic medications.
Aquila R; Emanuel M
J Clin Psychiatry; 1999 May; 60(5):336-7. PubMed ID: 10362443
[No Abstract] [Full Text] [Related]
35. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.
Czekalla J; Beasley CM; Dellva MA; Berg PH; Grundy S
J Clin Psychiatry; 2001 Mar; 62(3):191-8. PubMed ID: 11305706
[TBL] [Abstract][Full Text] [Related]
36. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
37. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
38. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
39. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
Sernyak MJ; Leslie DL; Alarcon RD; Losonczy MF; Rosenheck R
Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
[TBL] [Abstract][Full Text] [Related]
40. Adverse events related to olanzapine.
Conley RR; Meltzer HY
J Clin Psychiatry; 2000; 61 Suppl 8():26-9; discussion 30. PubMed ID: 10811240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
